Category Archives: Transhuman News

Epigallocatechin-3-gallate (EGCG), a polyphenol found in the leaves of green tea (Camellia sinensis), may increase levels of the natural anti-cancer protein p53, often referred to as the guardian of the genome, according to a new study led by Rensselaer Polytechnic Institute scientists.

Zhao et al. provide insights into the mechanisms for EGCGs anticancer activity and identifies p53 N-terminal domain as a target for cancer drug discovery through dynamic interactions with small molecules. Image credit: Sci-News.com.

Green tea, a popular beverage consumed worldwide, has been reported to have inhibitory effects against various types of cancer, such as breast, lung, prostate, and colon cancer.

Most of the chemo-preventive effects of green tea on cancer are attributed to polyphenol compounds, among which EGCG is the most important.

EGCG accounts for 50-80% of the catechin in green tea. There is 200-300mg of EGCG in a brewed cup (240mL) of green tea.

P53 has several well-known anti-cancer functions, including halting cell growth to allow for DNA repair, activating DNA repair, and initiating apoptosis if DNA damage cannot be repaired.

One end of the protein, known as the N-terminal domain, has a flexible shape, and therefore, can potentially serve several functions depending on its interaction with multiple molecules.

Both p53 and EGCG molecules are extremely interesting, said Rensselaer Polytechnic Institutes Professor Chunyu Wang.

Mutations in p53 are found in over 50% of human cancer, while EGCG is the major anti-oxidant in green tea, a popular beverage worldwide.

Now we find that there is a previously unknown, direct interaction between the two, which points to a new path for developing anti-cancer drugs.

Our work helps to explain how EGCG is able to boost p53s anti-cancer activity, opening the door to developing drugs with EGCG-like compounds.

Professor Wang and colleagues found that the interaction between EGCG and p53 preserves the protein from degradation.

Typically, after being produced within the body, p53 is quickly degraded when the N-terminal domain interacts with a protein called MDM2.

This regular cycle of production and degradation holds p53 levels at a low constant.

Both EGCG and MDM2 bind at the same place on p53, the N-terminal domain, so EGCG competes with MDM2, Professor Wang said.

When EGCG binds with p53, the protein is not being degraded through MDM2, so the level of p53 will increase with the direct interaction with EGCG, and that means there is more p53 for anti-cancer function. This is a very important interaction.

The study was published in the journal Nature Communications.

_____

J. Zhao et al. 2021. EGCG binds intrinsically disordered N-terminal domain of p53 and disrupts p53-MDM2 interaction. Nat Commun 12, 986; doi: 10.1038/s41467-021-21258-5

Read more:
Green Tea Compound Stabilizes 'Guardian of the Genome' Protein | Medicine - Sci-News.com

'); $("#expandable-weather-block .modal-body #mrd-alert"+ alertCount).append(""+val.title+""); // if (window.location.hostname == "www.kmov.com" || window.location.hostname == "www.kctv5.com" || window.location.hostname == "www.azfamily.com" || window.location.hostname == "www.kptv.com" || window.location.hostname == "www.fox5vegas.com" || window.location.hostname == "www.wfsb.com") { if (val.poly != "" && val.polyimg != "") { $("#expandable-weather-block .modal-body #mrd-alert"+ alertCount).append('"+val.ihtml+""); $("#expandable-weather-block .weather-index-alerts").show(); $("#expandable-weather-block .modal-body h2").css({"font-family":"'Fira Sans', sans-serif", "font-weight":"500", "padding-bottom":"10px"}); $("#expandable-weather-block .modal-body p").css({"font-size":"14px", "line-height":"24px"}); $("#expandable-weather-block .modal-body span.wxalertnum").css({"float":"left", "width":"40px", "height":"40px", "color":"#ffffff", "line-height":"40px", "background-color":"#888888", "border-radius":"40px", "text-align":"center", "margin-right":"12px"}); $("#expandable-weather-block .modal-body b").css("font-size", "18px"); $("#expandable-weather-block .modal-body li").css({"font-size":"14px", "line-height":"18px", "margin-bottom":"10px"}); $("#expandable-weather-block .modal-body ul").css({"margin-bottom":"24px"}); $("#expandable-weather-block .modal-body pre").css({"margin-bottom":"24px"}); $("#expandable-weather-block .modal-body img").css({"width":"100%", "margin-bottom":"20px", "borderWidth":"1px", "border-style":"solid", "border-color":"#aaaaaa"}); $("#expandable-weather-block .modal-body #mrd-alert"+ alertCount).css({"borderWidth":"0", "border-bottom-width":"1px", "border-style":"dashed", "border-color":"#aaaaaa", "padding-bottom":"10px", "margin-bottom":"40px"}); }); } function parseAlertJSON(json) { console.log(json); alertCount = 0; if (Object.keys(json.alerts).length > 0) { $("#mrd-wx-alerts .modal-body ").empty(); } $.each(json.alerts, function(key, val) { alertCount++; $("#mrd-wx-alerts .alert_count").text(alertCount); $("#mrd-wx-alerts .modal-body ").append(''); $("#mrd-wx-alerts .modal-body #mrd-alert"+ alertCount).append(""+val.title+""); // if (window.location.hostname == "www.kmov.com" || window.location.hostname == "www.kctv5.com" || window.location.hostname == "www.azfamily.com" || window.location.hostname == "www.kptv.com" || window.location.hostname == "www.fox5vegas.com" || window.location.hostname == "www.wfsb.com") { if (val.poly != "" && val.polyimg != "") { $("#mrd-wx-alerts .modal-body #mrd-alert"+ alertCount).append(''); } else if (val.fips != "" && val.fipsimg != "") { // $("#mrd-wx-alerts .modal-body #mrd-alert"+ alertCount).append(''); } // } //val.instr = val.instr.replace(/[W_]+/g," "); $("#mrd-wx-alerts .modal-body #mrd-alert"+ alertCount).append(val.dhtml+"

Instruction

Link:
WEEKENDS AT THE SCIENCE CENTER: Genome in Me - WFSB

Ensoma emerges with Series A funding and a collaboration deal with Takeda for its vector-delivered treatments.

Ensoma was backed in its Series A financing by 5AM Ventures and Takeda, amongst other investors, with $70 million (57 million).

Takedas investment occurs alongside an exclusive worldwide license to develop Ensomas Engenious vectors for up to five rare disease indications.

Image: iStock/yekorzh

The agreement includes a potential $100 million investment in upfront and preclinical research payments. Should the candidates progress past the preclinical stage, Ensoma is in line to receive up to $1.25 billion in additional development and commercialization milestones.

At the heart of the deal are Ensomas vectors, which the company states are designed to deliver genome modification technologies, such as genome editing through CRISPR/Cas9 or zinc finger nuclease.

This would allow Ensomas vectors to potentially treat rare monogenic diseases but, according to the company, also the possibility for broader disease indications in oncology or infectious diseases.

The vectors are engineered adenovirus vectors that do not contain any viral genome, allowing for storage space to deliver therapeutic cargo.

A spokesperson for Ensoma confirmed that it is currently working with unspecified contract manufacturing partners but that there are plans to bring manufacturing inhouse.

We are launching with significant process development and manufacturing expertise, the spokesperson added.

The company arrives with a chief technology officer in Daniel Leblanc, who previously led manufacturing, analytical development and drug product development for Flexion Therapeutics, a company developing an adenovirus-based gene therapy.

Regarding the complexity of producing Engenious vectors, the spokesperson stated that the process is much simpler and scalable compared to adeno-associated virus and lentiviral vector manufacturing.

Executive chairman of Ensoma, Paula Soteropoulos, announced on the companys launch that the plan is to deliver any treatments off-the-shelf, as no stem cell donors are required in their production and with no prior conditioning needing to take place.

The conditioning refers to patients who receive certain ex vivo gene therapy via lentiviral vectors undergoing chemotherapy prior to delivery.

Ensoma plans to administer its therapies through a single injection, potentially allowing the treatment to be delivered where access to sophisticated healthcare systems may be limited, the company states.

In terms of the next steps for the company, the spokesperson outlined that the Series A financing would allow the company to reach the investigational new drug (IND)-candidate nomination stage before it would need to raise additional equity. Ensoma plans to advance its own internal programs alongside those developed with Takeda.

Read more from the original source:
Ensoma launches to deliver off-the-shelf genomics - BioProcess Insider - BioProcess Insider

TBINGEN, Germany--(BUSINESS WIRE)--February 19, 2021 -- Illumina, Inc. (Nasdaq: ILMN) today announced an agreement with the Institute of Medical Genetics and Applied Genomics at the University Hospital of Tbingen to assess the value of whole-genome sequencing (WGS) as a first-line diagnostic test for patients with genetic diseases and familial cancer syndromes. Illumina will support the new investigator-initiated study, called the Ge-Med Project, with sequencing, analysis and health economic expertise.

The Institute is the first laboratory in Germany accredited to perform clinical WGS. Previously, it used whole exome sequencing for the diagnosis of rare disease conditions which involves sequencing only around 1% of the genome known to contain the coding regions that provide instructions for making proteins.

The move to WGS is based on a two-year feasibility study by the Institute, supported by Illumina, which found that WGS provided improved diagnosis across a range of rare diseases. For example, as many as 75% of genetic eye diseases were accurately diagnosed using WGS, including some forms of disease that could only be identified by sequencing the entire genome. Similar results were found for rare childhood cancers and for conditions that cause developmental delay in children.

In addition to expanding the range of conditions for diagnosis, the new study will examine the ability of WGS to generate scores for the risk of common diseases based on genomic data. Known as a polygenic risk score, this will help identify individuals that may benefit from personalized healthcare management.

We are delighted to be able to study whole genome sequencing as a diagnostic in an expanded range of conditions because we have demonstrated that it changes the management of patients who previously remained unresolved after whole exome and other sequencing approaches, said Tobias Haack, Head of Molecular Diagnostics at the Institute of Medical Genetics and Applied Genomics, University Hospital of Tbingen.

We are proud to support the University Hospital of Tbingen on this important step in their genomic work, said Dr. Phil Febbo, Chief Medical Officer, Illumina. Offering a clear diagnosis as well as disease risk for common conditions will give patients peace of mind and offer actionable steps to improve their overall health.

Professor Olaf Rie said, We know that the exome isnt the whole story when looking for answers to rare diseases and we have proven the value that WGS brings to families who otherwise would wait years for a diagnosis, or may never even receive one. Through the new study, we hope to help Germany lead the way in applying cutting edge genomics to improve healthcare.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit http://www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.

Continued here:
Illumina and the University Hospital of Tbingen Evaluate Potential of Whole Genome Sequencing to Improve Diagnosis of Full Range of Genetic Diseases -...

The Global Whole Genome Synthesis Market To Witness A Noteworthy Progression Over 2020-2026 byZion Market Research(ZMR) is a thorough assessment of the global Whole Genome Synthesis Market entailing the numerous factors applicable to market dynamics and growth. The report, by covering all the vital data and facts about the globalWhole Genome Synthesis Marketfor the forecast period of 2020 to 2026, will serve as a valued document for clients seeking guidance in decision-making intending to enter the market or strengthen their current market position. The report will put forth widespread data separated into different units that can further make the market understanding simpler.

Impact of COVID-19: The report will entail a dedicated unit about the influence of COVID-19 on market growth during the forthcoming years.

Request Free Sample Report of Whole Genome Synthesis Market Report @ https://www.zionmarketresearch.com/sample/whole-genome-synthesis-market

Market Players:The study comprises all the leading players contributing and competing in the global Whole Genome Synthesis Market. The key players areTwist Bioscience, J. Craig Venter Institute, Integrated DNA Technologies, Ansa Biotechnologies, and Icon Genetics.The report includes company profiles, their market shares, supply chain value, product specifications, etc. Also, it comprises the main strategic progress, such as new product launches, joint ventures, R&D activities, M&A, collaborations, and partnerships adopted by these players to attain a strong foothold in the market.

Key Aspects and Trends in the Market: The study presents the market overview entailing definition, synopsis, classifications, and applications. It further includes the in-depth evaluation of numerous factors that can possibly drive or obstruct the growth of the global Whole Genome Synthesis Market. Additionally, it entails the opportunities and risks for the global market during the projected timeline. The report also comprises the latest innovation, technological advancements, and key events in the market on a regional and global level together with the likely trends influencing the expansion of global Whole Genome Synthesis Market.

Segmentation and Regional Analysis:The study segregates the global Whole Genome Synthesis Market based on diverse factors such as Product, Applications, End-Users, and Major Regions. It also categorizes the market on the basis of key regions such as [North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America]. The segmentation and regional analysis include all the vital factors contributing to the growth of each segment and region in terms of revenues, market share, value, and so on.

Download Free PDF Report Brochure @https://www.zionmarketresearch.com/requestbrochure/whole-genome-synthesis-market

Global Whole Genome Synthesis Market: Regional Analysis

Highlights of Global Whole Genome Synthesis Market Report:

Apart from this, the study is a valuable source of all-inclusive facts and data for business strategists as it offers the historical as well as a futuristic approach about the market along with other factors such as revenue, demand & supply data, revenue, capacity, gross, production, production rate, consumption, import/export, gross margin, cost, and CAGR.

Inquire more about this report @https://www.zionmarketresearch.com/inquiry/whole-genome-synthesis-market

Why Choose Zion Market Research?

Frequently Asked Questions

Reasons for Buying this Report

Thanks for reading this article you can also get individual chapter-wise sections or region-wise report versions like North America, Europe, or Asia.

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the clients needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to usafter allif you do well, a little of the light shines on us.

Contact Us:

Zion Market Research244 Fifth Avenue, Suite N202New York, 10001, United StatesTel: +49-322 210 92714USA/Canada Toll-Free No.1-855-465-4651Email:sales@zionmarketresearch.comWebsite:https://www.zionmarketresearch.com

Read this article:
Global Whole Genome Synthesis Market To Witness A Noteworthy Progression Over 2020-2026 - The Courier

Horizon Europe is to allocate 5 million for projects aimed at understanding the benefits and risks of genome editing technologies in agriculture over the next two years, according to a leaked draft work programme.

Science|Business is publishing here all the draft Horizon Europe work programmes available to us. You can read them here. Or, if you have additional ones, you can send them to [emailprotected] (anonymously, if you wish.)

The move is in support of the Farm to Fork plan to reduce the use of fertilisers by 30 per cent and turn 25 per cent of agricultural land over to organic farming. To reach these objectives, the Commission says the EU needs to enable major advances in the life sciences and biotechnology, in new genomic techniques, such as gene/genome editing.

Plans for the 5 million call come after EU agriculture ministers called on the Commission last October to enable the use of new innovative ingredients and techniques to boost sustainable food production, once they are shown to be safe for humans, animals and the environment. The headline figure for the call is only indicative, and the Commission could fund proposals that go beyond this figure.

Also last October, French scientist Emmanuelle Charpentier, director at the Max Planck Institute for Infection Biology in Berlin, and her collaboration partner Jennifer Doudna, were awarded the Nobel prize in chemistry for the development of a method for genome editing.

But as things stand, precision breeding of plants with gene editing technologies cannot be used in the EU, following a 2018 ruling by the European Court of Justice (ECJ), which founds genome editing is subject to the 2001 EU directive banning genetically modified organisms (GMOs).

In an early post-Brexit move, the UK last month launched an industry consultation on gene editing, as it seeks to move away from EU regulations on genetically modified organisms (GMOs). Depending on the outcome, there will be a second consultation on changing the definition of a GMO. The UK government view is that organisms produced by gene editing or by other genetic technologies, should not be regulated as GMOs if they could have been produced by traditional breeding methods.

The proposed 5 million for genome editing research is a small part of a total of 1.83 billion that is to be spent in 2021 and 2022 on Horizon Europes sixth cluster on food, bioeconomy natural resources, agriculture and environment, the draft work programme from December 2020 has revealed.

The European Commission is expected to publish the official work programmes with final funding figures and deadlines for application by the end of April. However, many research stakeholders have had access to draft versions of the documents posted online. Science|Business has published a trove of such documents, which offer researchers a detailed insight of how the 95.5 billion funding programme will be organised.

Call to lift gene editing ban

Research stakeholders have been calling on the EU to lift restrictions on genetically modified crops, to allow the use of genome editing, which need not involve the introduction of foreign genes. In 2020, in a report by the European Federation of Academies of Sciences and Humanities, researchers in 120 institutions across Europe appealed to the Commission to help reverse the ECJ ruling.

According to the report, the policy change would help Europe develop more productive, climate-friendly, and resilient crops, and bring the EU up to date with recent scientific developments. These new technologies may contribute to a reduction of the environmental footprint of agriculture, the researchers said.

While agriculture ministers expect the Commission to complete a study of the status of novel genomic techniques under EU legislation by April, the Horizon call is still asking researchers to align their proposals with existing EU laws, including the infamous ECJ ruling of 2018.

Proposals are expected to advance new genomic techniques in bio-based innovation and to assess potential critical impacts and bottlenecks with respect to the EU and international governance frameworks.

Other priorities

According to the draft work programme, the Commission is planning to allocate 404 million over the next two years for research projects supporting its Farm to Fork strategy.

The Commission is also looking for proposals to explore the evolution and spread of microbiomes in the wild and their relationship with biodiversity loss and the growing risk of epidemics.

A 15 million call will be reserved for projects developing innovative digital tools tailored to the needs of small- and medium-sized farms. The Commission wants farmers to increase their uptake of digital technologies and prevent an increased digital divide between small and large farms.

The Commission is also planning to allocate 230 million over the next two years on projects addressing the EUs push for a circular economy, by significantly reducing waste and promoting continuous recycling of natural resources.

The projects are expected to improve material selection and product design, but also to promote new value chains and business models focused on the upgrade, refurbishment and remanufacturing, of products to reduce waste.

Some calls will be dedicated to projects that seek to make EUs industry more sustainable and reduce its dependence on resources, by lowering the use of primary non-renewable raw materials.

Go here to see the original:
Horizon Europe to fund research on genome editing in agriculture - Science Business

Abstract

An R loop is a unique triple-stranded structure that participates in multiple key biological processes and is relevant to human diseases. Accurate and comprehensive R loop profiling is a prerequisite for R loops studies. However, current R loop mapping methods generate large discrepancies, therefore an independent method is in urgent need. Here, we establish an independent R loop CUT&Tag (Tn5-based cleavage under targets and tagmentation) method by combining CUT&Tag and GST-His6-2HBD (glutathione S-transferasehexahistidine2 hybrid-binding domain), an artificial DNA-RNA hybrid sensor that specifically recognizes the DNA-RNA hybrids. We demonstrate that the R loop CUT&Tag is sensitive, reproducible, and convenient for native R loop mapping with high resolution, and find that the capture strategies, instead of the specificity of sensors, largely contribute to the disparities among different methods. Together, we provide an independent strategy for genomic profiling of native R loops and help resolve discrepancies among multiple R loop mapping methods.

An R loop is a special triple-stranded nucleic acid structure formed when nascent RNA invades double-stranded DNA (dsDNA) during transcription, resulting in a DNA-RNA hybrid and a displaced single-stranded DNA (ssDNA). R loops are widely present from bacteria to mammals (1). Although R loops have been considered as mere by-products of transcription, growing evidence shows that they participate in various key biological processes, such as genome stability maintenance (1), transcriptional regulation (2, 3), DNA damage repair (4, 5), and regulation of chromatin landscape (6, 7). Recently, dysfunction in regulation of R loops has been shown to associate with multiple human diseases, including cancers, neurological diseases, and immune disorders (8, 9).

Studying the functions and regulation of R loops in physiological and pathological processes relies on accurate and comprehensive profiling of R loops in the human genome (10). During the past decade, several genome-wide R loop mapping methods were developed, using either the S9.6 monoclonal antibody (mAb) or catalytically inactive ribonuclease (RNase) H1 for specific DNA-RNA hybrid (a defining feature of R loops) binding and capturing (11). Currently, the predominant strategy for genome-wide profiling of R loops is the DNA-RNA immunoprecipitation sequencing (DRIP-seq), which captures DNA-containing R loop fragments using the S9.6 antibody before sequencing (1217). DRIPc-seq is derived from DRIP-seq and specifically sequences the RNA component of the hybrid (18). However, the specificity of the S9.6 antibody has been questioned recently for accurate quantification and mapping of genuine R loops (11, 19, 20). Moreover, the digestion efficiency and bias in chromatin fragmentation by restriction enzymes could potentially compromise R loop mapping resolution in DRIP-related approaches (21).

R loop chromatin immunoprecipitation (R-ChIP) takes advantage of the natural affinity of RNase H1 to DNA-RNA hybrids (22). An exogenous catalytically inactive RNase H1 was expressed intracellularly to bind DNA-RNA hybrids without resolving them. The DNA (23, 24) or the RNA component (RR-ChIP) (25) of the hybrids was sequenced by ChIP assays with V5-tagged RNase H1. R-ChIP/RR-ChIP provides a new perspective of R loop mapping. However, intracellular expression of exogenous catalytically inactive RNase H1 is time consuming, and this mutant RNase H1 could compete with endogenous enzymes for DNA-RNA hybrid binding, which may affect the native R loop status. Alternatively, catalytically inactive RNase H1 was combined with affinity pulldown assays [DNA-RNA in vitro enrichment coupled to sequencing (DRIVE-seq)] or cleavage under targets and release using nuclease (MapR) to map the R loops (12, 26). Nevertheless, DRIVE-seq is less sensitive than DRIP-seq, and its application is limited (8, 12).

R loops participate in multiple biological processes, especially transcription elongation. R loops have been shown to impair transcription elongation by functioning as roadblocks, and R loops are also correlated with transcription pausing near gene promoters (24, 27, 28). Since dysfunction of R loops and transcription elongation control are implicated in human diseases (29), precise and comprehensive mapping of R loops is crucial for studying the functions and mechanisms of R loops in these diseases. Different R loop mapping methodologies have been shown to generate large discrepancies in R loop profiling, especially the genomic distribution of R loops (8, 9, 11, 23). For example, R-ChIP and MapR (26) both use catalytically inactive RNase H1 and show that R loops are condensed at promoters and almost absent at the 3 end of genes, whereas DRIP-seq and its derivatives show appreciable signals starting at 2-kb downstream of gene promoters, and much higher signals in the gene body and the 3 end of genes. The disparities may be caused by the different specificities of RNase H1 and S9.6 to R loops or the different R loop capture and sequencing strategies, such as R loop capture in situ or ex vivo. Moreover, the recombinant catalytically inactive full-length RNase H1 is not very efficient in affinity pulldown (8, 12), which is the principle of DRIP-related R loop mapping methods. Therefore, R loop mapping methodology independent of S9.6 or catalytically inactive RNase H1 is urgently needed to clarify the controversies.

The N-terminal hybrid-binding domain (HBD) of RNase H1 is a short-protein domain, composed of a three-stranded antiparallel sheet and two short helices. HBD mediates the specific recognition of DNA-RNA hybrids in a nonsequence-specific manner (22), which highlights the domain itself as a potential sensor for R loop mapping. Recently, Tn5 transposase was reported to randomly bind DNA-RNA hybrids and transpose adapters onto both strands of the DNA-RNA hybrids (30, 31). Besides, the transposed products could have the strand displaced and be directly used for sequencing library preparation, which save many time-consuming steps (30, 31). Using the Tn5 system for DNA and DNA-RNA hybrids tagmentation would potentially avoid fragmentation bias caused by restriction enzyme digestion.

To test the possibility of using the HBD and Tn5 transposase for R loop profiling, we constructed two glutathione S-transferase (GST)tagged and hexahistidine (His6)tagged artificial sensor proteins (GST-His6-HBD and GST-His6-2HBD) with tandem repeats of HBD and established an independent system for native R loop mapping. First, we found that the HBD-containing sensor proteins exhibit high specificity to DNA-RNA hybrids compared to other nucleic acid structures in vitro and GST-His6-2HBD protein behaves similarly to the S9.6 antibody in DRIPc-seq. Furthermore, we combined the R loop sensor protein GST-His6-2HBD or S9.6 with the recently developed Tn5-based cleavage under targets and tagmentation (CUT&Tag) technology (32, 33) and established a native R loop mapping method called R loop CUT&Tag. Compared to conventional R loop mapping methods, R loop CUT&Tag provides superior and highly specific R loop signals at the promoters and is able to detect transient R loops at the gene body and enhancer regions. Together, our study clarifies the controversies among different R loop mapping methods, by providing an independent methodology that accurately and comprehensively profiles the native R loops across the genome.

In an attempt to overcome the limits of the S9.6 antibody and catalytically inactive full-length RNase H1, we took advantage of the DNA-RNA hybrid binding proprieties of the N-terminal HBD domain of RNase H1 (22), which contains a three-stranded antiparallel sheet and two short helices (Fig. 1A). For specific DNA-RNA hybrid recognition in vitro, we designed two GST- and His6-tagged sensor proteins (GST-His6-HBD and GST-His6-2HBD) with tandem repeats of HBD separated by a flexible 5Glycine linker (Fig. 1A). These proteins were expressed in T7 Express lysY/Iq bacteria cells and were affinity-purified by Ninitrilotriacetic acid (NTA) agarose beads (Fig. 1B and fig. S1A). To measure the interaction of recombinant sensor proteins with different forms of nucleic acid structures, including ssDNA, dsDNA, single-stranded RNA (ssRNA), double-stranded RNA (dsRNA), and DNA-RNA hybrid, we tested the affinity of recombinant GST-His6-HBD (fig. S1, B to F) and GST-His6-2HBD (Fig. 1, C to G) by electrophoretic mobility shift assay (EMSA) analysis using the fluorescently labeled 25-mer probes and the purified sensor proteins.

(A) Schematic depiction of the domain structure of RNase H1 protein. The HBD domain of RNase H1 is responsible for the specific recognition of the DNA-RNA hybrids (22). GST-His6-HBD and GST-His6-2HBD expression constructs are shown below. (B) Analysis of the purified GST-His6-HBD and GST-His6-2HBD proteins by SDSpolyacrylamide gel electrophoresis (PAGE) and Coomassie blue staining. (C to G) EMSAs showing GST-His6-2HBD prefers the DNA-RNA hybrid (C), compared to ssDNA (D), dsDNA (E), ssRNA (F), and dsRNA (G). Fluorescent probes (30 nM) were incubated with increasing concentrations of GST-His6-2HBD (2HBD) as the indicator for binding. The complexes were resolved with a 6% native polyacrylamide gel and were imaged with a Typhoon FLA-9500. GST-His6-2HBD: DNA-RNA hybrid complexes are indicated by a bracket. (H) Biolayer interferometry assay of DNA-RNA hybrid and GST-His6-2HBD. Biotinylated DNA-RNA hybrid was immobilized on streptavidin biosensors and incubated with a range of GST-His6-2HBD (from 6.25 to 200 nM) to measure the response in an Octet Red96 instrument. (I) EMSAs analysis of GST-His6-2HBD with probes of different GC contents.

EMSA analysis showed that both GST-His6-HBD (fig. S1, B to F) and GST-His6-2HBD (Fig. 1, C to G) had the highest affinity for DNA-RNA hybrid, yet little affinity for ssDNA, dsDNA, ssRNA, and dsRNA. dsRNA showed weak interaction with GST-His6-2HBD at high concentrations (Fig. 1G). The results demonstrate that the recombinant GST-His6-HBD and GST-His6-2HBD proteins preferentially interact with the DNA-RNA hybrid. Quantitative analysis of recombinant proteins with biotin-labeled DNA-RNA hybrid probes by biolayer interferometry revealed a 10.4 nM dissociation constant Kd for the complexes of GST-His6-2HBD:DNA-RNA hybrid (Fig. 1H), and 16.5 nM for GST-His6-HBD:DNA-RNA hybrid complexes (fig. S1G), respectively. Furthermore, we checked the sequence specificity of GST-His6-2HBD with different probes of various guanine-cytosine (GC) contents and found that GST-His6-2HBD did not have obvious GC preference in DNA-RNA hybrids (Fig. 1I). Further quantification of three biological replicates of EMSA experiments using free probes showed that 0% GC substrate had a slightly weaker binding with 1600 nM GST-His6-2HBD than other probes (fig. S1H). We also confirmed that GST-His6-2HBD could bind the three-stranded R loop structure (fig. S1I). Testing GST-His6-2HBD with probes of different lengths in EMSA (fig. S1, J to L) showed that the 25-mer probe had a slightly stronger interaction with GST-His6-2HBD than the 12-mer probe, while the 48- and 25-mer probe had similar binding to GST-His6-2HBD. Together, these data suggest that the recombinant HBD sensor proteins can be potentially used in R loop profiling as specific DNA-RNA hybrid recognition modules. We chose the GST-His6-2HBD for the rest of the studies, because of its slightly higher affinity with the DNA-RNA hybrid.

As GST-His6-2HBD specifically bound DNA-RNA hybrid and R loop in vitro, we then investigated whether it could replace the S9.6 antibody in the DRIPc-seq assay, in which DNA-RNA hybrids are immunoprecipitated with the antiDNA-RNA hybrid S9.6 antibody and the associated RNA molecules are sequenced in a stranded manner to map R loops (18). We established a similar DRIPc-seq method with GST-His6-2HBD using the same restriction enzymes, R loop enrichment strategy, and RNA-based library preparation as the S9.6-based DRIPc-seq (Fig. 2A) (18). First, we optimized the restriction digestion, amount of GST-His6-2HBD for DNA-RNA hybrid immunoprecipitation, and library preparation for GST-His6-2HBDbased DRIPc-seq (fig. S2, A to C). After optimization, we successfully profiled the genome-wide R loop signals with GST-His6-2HBD as shown in Fig. 2 (B and C) and fig. S2D. Since R loop formation requires transcription elongation of RNA polymerase II (Pol II), we also performed precision nuclear run-on sequencing (PRO-seq) and transient transcriptome sequencing (TT-seq) for genome-wide mapping of the elongating Pol II in human embryonic kidney (HEK) 293T cells (Fig. 2, B and C, and fig. S2D). University of California, Santa Cruz (UCSC) genome browser tracks of our 2HBD-DRIPc-seq data revealed similar profiles as the published S9.6-based DRIPc-seq (GSE102474) (34) at individual genomic loci (Fig. 2, B and C, and fig. S2D).

(A) Schematic presentation of DRIPc-seq with GST-His6-2HBD protein. (B and C) UCSC genome browser tracks of 2HBD-DRIPc-seq, DRIPc-seq (GSE102474) (34), PRO-seq, and TT-seq reads density at the NCK2, UXS1 (B), MRPS9, and POU3F3 (C) loci. Read density was normalized by reads per million (r.p.m.). (D) Heatmap and metagene plots of 2HBD-DRIPc-seq, the published DRIPc-seq, PRO-seq, and TT-seq signals in the plus and minus strands. (E) Scatter plot of the 2HBD-DRIPc-seq counts and S9.6DRIPc-seq counts with all of the protein-coding genes. The Pearson correlation coefficient is shown. (F) The genome-wide Pearson correlation heatmap of 2HBD-DRIPc-seq, S9.6-DRIPc-seq, and TT-seq showing densities within all protein-coding genes.

To compare 2HBD-DRIPc-seq and S9.6-DRIPc-seq in the genome-wide scale, we plotted the heatmap and metagene plots at all of the protein-coding genes on both minus and plus strands. The results revealed that 2HBD-DRIPc-seq had well-correlated profiles as S9.6-DRIPc-seq, and the R loop signals mostly localize at the downstream of promoter, gene body, and transcription end site (TES) (Fig. 2D). Quantitative analysis of 2HBD-DRIPc-seq and S9.6-DRIPc-seq also revealed a high Pearson correlation coefficient of 0.799 (Fig. 2E). Besides, the DRIPc-seq signals generated from both GST-His6-2HBD and S9.6 were positively correlated with elongating Pol II as represented by TT-seq and PRO-seq densities (Fig. 2F and fig. S2, E and F). Since R loops are cotranscriptionally generated, we isolated and sequenced the RNA tethered with chromatin to identify the nascent RNA transcripts (fig. S3A). Genome browser track examples showed that the chromatin-associated RNA sequencing (RNA-seq) profile was similar to GST-His6-2HBD and S9.6-based DRIPc-seq (fig. S3B), and genome-wide analysis of these signals indicated that they were well correlated (fig. S3, C and D). Together, these results demonstrate that the GST-His6-2HBD sensor protein could be used in affinity pulldown assays and exhibits similar profiles as the S9.6 antibody in the DRIPc-seq assays.

The DRIP-based R loop mapping techniques use a combination of restriction enzymes to digest genomic DNA before immunoprecipitation and subsequent next-generation sequencing. The restriction enzymes were reported to be biased and could not fragment the genome uniformly, leading to decreased resolution of DRIP-based R loop profiling (21). To avoid potential interference of genomic DNA fragmentation and check the possibility of using GST-His6-2HBD for native R loop profiling, we tested the GST-His6-2HBD sensor protein and the S9.6 antibody with CUT&Tag (32, 33) for in situ and fragmentation-free R loop mapping. First, we constructed and purified a protein Atethering Tn5 transposase (pA-Tn5) with Ni-NTA affinity purification and performed the pA-Tn5 transposome assembly with adapters (see Materials and Methods). Next, we designed the CUT&Tag workflow for native R loop mapping (Fig. 3A), which used Bst 2.0 WarmStart DNA polymerase for strand displacement followed by library amplification (Fig. 3B). In the CUT&Tag analysis, we designed three different approaches to mapping the native R loops: The first approach used the GST-His6-2HBD and an anti-GST antibody for GST-tagged protein recognition; the second approach also relied on GST-His6-2HBD but required the binding of an anti-HisTag antibody; and the last approach used the S9.6 antibody for R loop detection. The Tn5-based chromatin profiling methods raised concerns of potential tagmentation of accessible DNA, which may generate assay for transposase-accessible chromatin sequencing such as signals (35). We used RNase A to evaluate this potential artifact, since the DNA-RNA hybrids are resistant to RNase A digestion at high salt concentrations (>300 mM) and become highly sensitive to RNase A with decreasing salt concentrations. We evaluated all these three approaches with digesting the RNA and DNA-RNA hybrids using RNase A (Fig. 3C).

(A) Overview of the R loop CUT&Tag workflow. Cells were immobilized on concanavalin A (ConA)coated magnetic beads, followed by cell permeabilization. GST-His6-2HBD or S9.6 is used to recognize the R loops in the presence or absence of RNase A. Anti-GST, anti-HisTag, or secondary antibodies were applied to enhance the tethering of pA-Tn5 transposome at the GST-His6-2HBD or S9.6-bound sites. After extensive wash, the pA-Tn5 transposome is activated to integrate the adapters on the chromatin. (B) CUT&Tag library preparation with Bst 2.0 WarmStart and Q5 polymerase. Strand displacement was performed with Bst 2.0, followed by library amplification with Q5 DNA polymerase. (C) Three different approaches for R loop CUT&Tag analysis. (D) LabChip analysis of R loop CUT&Tag library demonstrating the library size ranges from 220 to 700 bp with an average size of 405 bp. UM, upper marker; LM, lower marker. (E) Alignment rates of R loop CUT&Tag reads to the human hg38 and E. coli spiked-in genomes. RNase A treatment markedly decreases the alignment rates of CUT&Tag reads to the human genome, suggesting the specificity of GST-His6-2HBD and S9.6 on R loop recognition. (F) UCSC genome browser tracks of CUT&Tag signals at the NPM1 and YY1AP1 loci. The tracks were normalized by reads per million, and the RNase Atreated groups were further normalized with the E. coli spike-in control.

First, we optimized the Tn5-mediated tagmentation in S9.6-based CUT&Tag with different additives such as 0.85 mM adenosine 5-triphosphate (ATP), 10% N,N-dimethylformamide (DMF), and 9% polyethylene glycol, molecular weight 8000, as suggested by a recent Tn5-based DNA-RNA hybrid tagmentation study (30). Supplementing 10% DMF markedly enhanced the tagmentation, while the addition of 0.85 mM ATP further improved the effect (fig. S3E). With the improved tagmentation, we generated CUT&Tag sequencing libraries ranging from 220 to 700 base pairs (bp), with the average size of around 405 bp (Fig. 3D). Because of the concomitant Escherichia coli genomic DNA during pA-Tn5 transposase protein production, we used the DNA derived from the E. coli genome for spike-in normalization, as reported by a previous study (32). After alignment of R loop CUT&Tag reads to the human hg38 and the E. coli genomes, we noticed that RNase A treatment markedly decreased the alignment rates of CUT&Tag reads to the human genome and increased the percentages of E. coli reads with all three different approaches (Fig. 3E). As shown in Fig. 3F and fig. S3F, we detected the R loop signals at the transcription start site (TSS) of the representative genes NPM1 and YY1AP1, as well as R loop signals in the gene body (fig. S3F), while RNase A digestion led to marked reduction of signals at these loci, suggesting that the R loop CUT&Tag signals are not artifacts due to the DNA accessibility.

To comprehensively compare the three aforementioned approaches for R loop CUT&Tag, we performed peak calling and analyzed the distribution of R loop signals over the human genome. The results revealed a high degree of similarity as shown in the heatmap and metaplot analysis (Fig. 4A). Heatmap profiles of R loop CUT&Tag demonstrated that these R loop signals are highly sensitive to RNase A treatment (Fig. 4B). Most of R loop signals within all three approaches localize at the promoter, while some of these signals could distribute in the gene body and intergenic region (Fig. 4C and table S1). Compared with S9.6, GST-His6-2HBD exhibited narrower peak width in CUT&Tag analysis, indicating a slightly better resolution of GST-His6-2HBD for R loop mapping (Fig. 4D). Moreover, the second approach using the GST-His6-2HBD and an anti-HisTag antibody showed the strongest R loop signals (Fig. 4B) and appeared be the most sensitive approach to RNase A digestion (Fig. 4, E and F). Overall, R loop signals generated from all three different approaches were very similar, and their densities were highly and positively correlated with each other (Fig. 4, G to I). Together, these data demonstrate that both S9.6 and GST-His6-2HBD can be used in R loop CUT&Tag analysis and they generate highly similar native R loop profiles.

(A) Analysis of R loop CUT&Tag signals at all of the peaks from GST-His6-2HBD and S9.6 CUT&Tag. RNase A digestion markedly reduced the CUT&Tag signals at those peaks, suggesting great specificity of GST-His6-2HBD and S9.6 with R loops. (B) Heatmap profiles of CUT&Tag signals with or without RNase A treatment. (C) Annotation of CUT&Tag peaks showing the localization of the majority of R loops at the promoter regions. The genomic features are shown on the right. UTR, untranslated region. (D) Violin plot of CUT&Tag peak width with three different approaches. Wilcoxon test was used to test the statistical differences. CUT&Tag analysis with anti-HisTag antibody and GST-His6-2HBD provides a superior resolution of R loop mapping. (E and F) Scatter plots of the log2 fold changes of R loop signals detected by anti- HisTag with RNase A (+/) versus the log2 fold changes of anti-GST and RNase A (+/) (E) or log2 fold changes of S9.6 and RNase A (+/) (F). CUT&Tag analysis with anti-HisTag antibody and GST-His6-2HBD is the most specific approach for R loop mapping. (G to I) Scatter plots of CUT&Tag signals from three different approaches. Pearson correlation was performed, and the r values are shown.

Furthermore, we tested the sensitivity of R loop CUT&Tag signals to RNase H, which digests DNA-RNA hybrid. As shown in Fig. 5 (A to D), RNase H treatment markedly decreased the R loop signals at individual genes such as NPM1, YY1AP1, FUS, and RPL13A. We also found that RNase H treatment decreased the alignment rates of CUT&Tag reads to the human genome and increased the percentages of E. coli reads in both GST-His6-2HBD and S9.6 antibodybased R loop CUT&Tag (Fig. 5E), which had a similar trend as RNase Atreated R loop CUT&Tag (Fig. 3E). Heatmap and metaplot analysis of R loop CUT&Tag signals at all of the peaks from GST-His6-2HBD and S9.6 CUT&Tag confirmed the substantial reduction of R loop signals after RNase H treatment (Fig. 5, F and G), which demonstrates specificity of GST-His6-2HBD and S9.6 in R loop CUT&Tag. We also noticed that RNase H treatment did not completely abolish the CUT&Tag signals, which is consistent with a recent study (36) showing that a subset of DNA-RNA hybrids with high GC skew are partially resistant to RNase H. This result may be attributed to the digestion efficiency of commercial RNase H (18, 36) or the potential protection of DNA-RNA hybrids by some R loop binding proteins. Moreover, to measure the reproducibility of R loop CUT&Tag analysis, we performed independent studies at different days and found high reproducible results across independent biological replicates with the R loop CUT&Tag methods (Fig. 5, H to J). Together, these data suggest that GST-His6-2HBD and S9.6 are specific and reproducible for native R loop mapping in CUT&Tag analysis.

(A to D) UCSC genome browser tracks of CUT&Tag signals at the NPM1, RPL13A, YY1AP1, and FUS loci. The tracks were normalized by reads per million and the RNase Htreated groups were further normalized with the E. coli spike-in control. (E) Alignment rates of R loop CUT&Tag reads to the human hg38 and E. coli spiked-in genomes. Four-hour RNase H treatment markedly reduces the alignment rates of CUT&Tag reads to the human genome and increases the alignment rates of reads to E. coli spiked-in genomes. (F and G) Heatmap and metaplot analysis of R loop CUT&Tag signals at all of the peaks from GST-His6-2HBD and S9.6 CUT&Tag. RNase H digestion markedly decreases the CUT&Tag signals at those peaks, demonstrating great specificity of GST-His6-2HBD and S9.6 on R loop recognition. (H to J) Reproducibility of R loop CUT&Tag methods. Biological replicates were performed, and the Pearson correlation was calculated with the reads per million at R loop peaks.

To systematically compare the R loop CUT&Tag methods with conventional R loop mapping methods, we downloaded the raw data of R loop profiles generated by MapR (26), R-ChIP (24), and DRIPc-seq (34) and realigned them to the human genome hg38. As illustrated in Fig. 6 (A and B), R loop CUT&Tag with GST-His6-2HBD or S9.6 had similar patterns as R-ChIP and MapR, showing concentrated signals at TSS sites, whereas R loop CUT&Tag had much higher overall signal densities. R loop CUT&Tag was different from DRIPc-seq, which distributes highly across the gene body and TES regions. Principal components analysis (PCA) and correlation analysis of these data confirmed that R loop CUT&Tag clustered together with R-ChIP and MapR, and they were distinctly away from DRIPc-seq, PRO-seq, and TT-seq (Fig. 6C and fig. S4A). Moreover, the fingerprint plot of R loop CUT&Tag, R-ChIP, and MapR showed that R loop CUT&Tag had the highest signal-to-noise ratio in R loop profiling (Fig. 6D).

(A and B) Track examples of HEK293T PRO-seq, GST-His6-2HBD CUT&Tag, S9.6 CUT&Tag, MapR (26), R-ChIP (24), DRIPc-seq (34), and TT-seq signals at the HSPD1 (A) and GRK6 (B) loci. The reads were aligned to the human hg38 genome, and the signals were normalized by reads per million. (C) PCA plot showing R loop CUT&Tag, MapR, and R-ChIP clustered together. (D) Fingerprint plots of R loop CUT&Tag, MapR, and R-ChIP. w.r.t., with respect to. (E and F) Metaplots of signals detected by different R loop mapping methods, PRO-seq, and TT-seq around the 2-kb window of the TSSs and TESs. Strand-specific signals from PRO-seq, TT-seq, DRIPc-seq, and R-ChIP were used for plotting. (G) Heatmap analysis of PRO-seq, TT-seq, and R loop mapping methods at the TSS of transcriptionally active genes (the reads per million of PRO-seq signals at TSS, >1; n = 13,220). The heatmaps are sorted by the GST-His6-2HBD CUT&Tag signals. R loop CUT&Tag assays, MapR, and R-ChIP have enrichment at the TSS, while DRIPc-seq does not show this trend. (H and I) Scatter plots of R loop CUT&Tag and MapR reads per kilobase, per million mapped reads (RPKM) values (H) or R-ChIP RPKM values (I) at TSS. The r values were calculated by Pearson correlation.

To compare the genome-wide R loop signals among different methods, we selected all of the expressed genes presenting PRO-seq signals at the TSS sites [the reads per million of PRO-seq signals at TSS, >1; n = 13,220] in HEK293T cells. Metaplot, metagene plot, and heatmap analysis with these genes showed that CUT&Tag, MapR, and R-ChIP signals were highly concentrated at the TSS sites (Fig. 6, E to G, and fig. S4, B and C). The overall enrichment of R loop signals by CUT&Tag was much higher than other R loop mapping methods including MapR and R-ChIP. In agreement with previous studies (15, 23), we noticed the benefits of R-ChIP for strand-specific R loop mapping, while DRIPc-seq signals distributed across the gene body and TES regions (Fig. 6F and fig. S4, B and C). Besides, we found that the R loop densities at the promoter region generated by CUT&Tag, R-ChIP, and MapR were positively correlated (Fig. 6, H and I). Together, these results demonstrate that R loop CUT&Tag with either GST-His6-2HBD or S9.6 behaves similarly to R-ChIP and MapR but shows much higher R loop enrichment than R-ChIP and MapR at promoter regions. Since these R loop mapping methods use different R loop capture strategies, our data suggest that the capture strategies may substantially affect the R loop profiling.

As shown in Fig. 6 (A and B), R loop CUT&Tag signals were distributed at both the promoter and gene body regions. Next, we performed genome-wide assessment of the R loop signals by calculating the densities [reads per kilobase, per million mapped reads (RPKM)] of R loop at the TSS and gene body regions (Fig. 7A). We successfully calculated 13,181 genes with R loop signals at the TSS sites of the 13,200 expressed genes. Box plots of RPKM from the 13,181 transcriptional active genes showed that TSS densities generated from CUT&Tag, R-ChIP, and MapR were higher than densities at the gene body (Fig. 7B), which is consistent with the metagene analysis (fig. S4B). Furthermore, we noticed the variability of CUT&Tag densities at the gene body regions, suggesting high heterogeneity of densities at gene body among transcriptional active genes as measured by R loop CUT&Tag (Fig. 7B). Therefore, we further plotted the R loop CUT&Tag signals at the TSS and gene body and found that densities at the gene body had a bimodal (two peaks) distribution pattern (Fig. 7C), whereas this bimodal distribution pattern was not observed in R-ChIP or MapR (Fig. 7, D and E). These observations indicate that R loop CUT&Tag is capable of genome-wide detection of R loop. Together, these results suggest that R loop CUT&Tag is more sensitive than R-ChIP and MapR for R loop detection at the gene body regions.

(A) Scheme of calculation of signals at TSS and gene body. The signals were normalized by RPKM. (B) Box plots of RPKM values at the TSS and gene body from 13,181 transcriptional active genes. (C) Scatter plot of R loop CUT&Tag signals at the TSS and gene body showing that R loop CUT&Tag is capable of genome wide detecting the R loop in the gene body. (D and E) Scatter plots of MapR (D) and R-ChIP (E) RPKM signals at the TSS and gene body. (F) Heatmap plots of the 3769 genes with R loop signals at gene body (G and H) The R loop signals at gene body were negatively correlated with gene lengths. (I and J) The gene body R loop signals positively correlate with PRO-seq (I) and H3K36me3 (J) signals at the gene body. (K) Gene ontology (GO) analysis of the 3769 genes indicates that R loop may be involved in the regulation of various key biological processes. (L) Track examples of HEK293T PRO-seq, GST-His6-2HBD CUT&Tag, and S9.6 CUT&Tag signals at the YY1 and ZNF557 genomic loci. The reads were normalized by reads per million, and the enhancers are indicated. (M) Heatmap analysis of R loop CUT&Tag signals at 3830 intergenic regions. The heatmaps were sorted by the GST-His6-2HBD CUT&Tag signals, and the H3K27ac signals in HEK293T are shown. H3K27ac, histone 3 lysine 27 acetylation.

With the aforementioned strategy, we identified 3769 genes (Q1) with R loop densities at the gene body using the cutoffs indicated in Fig. 7C (table S2). Heatmap plots of these 3769 genes confirmed R loop signals at the gene body detected by R loop CUT&Tag (Fig. 7F). We further analyzed the genomic features of the 3769 genes and found that these genes were generally clustered together (Fig. 6B) and associated with short gene lengths (Fig. 7, G and H). Since elongating Pol II is required for R loop formation at gene body, we calculated the PRO-seq and histone 3 lysine 36 trimethylation (H3K36me3) (GSE145160) (37) signals at the gene body and found that R loop densities were positively correlated with PRO-seq signals and H3K36me3 densities at gene body (Fig. 7, I and J), suggesting the authenticity of R loop signals at gene body and that these R loops may associate with transcription elongation. Gene ontology analysis of the 3769 genes showed that they were enriched in multiple cellular processes (Fig. 7K) including cellular component organization or biogenesis, developmental process, metabolic process, and cell growth, indicating that R loops at gene body may participate in the regulation of various key biological processes.

Because of the short half-lives of enhancer RNAs and low transcriptional outputs of enhancers, R loops formed at enhancers are likely to be transient and dynamic. However, we still observed R loop CUT&Tag signals at enhancer regions as shown in Fig. 7L. Annotation of R loop CUT&Tag peaks revealed a subset of R loop peaks localized at the intergenic regions (Fig. 4C and table S1). Genome-wide analysis of R loop CUT&Tag peaks identified 3830 intergenic regions, and the heatmap analysis also confirmed that R loop CUT&Tag signals could distribute at these intergenic regions (Fig. 7M). Together, these data indicate that R loop CUT&Tag is sensitive in detecting the transient and dynamic R loops at enhancers.

As shown in Fig. 6 and fig. S4, the ex vivo or in situ capture strategies may substantially affect the R loop profiling in the genome. To systematically compare the difference between the ex vivo and in situ capture strategies, we established a modified DRIPc-seq method with random fragmentation by the New England Biolabs (NEB) dsDNA fragmentase to avoid the bias of restriction digestion (Fig. 8A) (21). We tested both the GST-His6-2HBD and S9.6 in the modified DRIPc-seq and compared them to R loop CUT&Tag analysis. Genome browser snapshots at the FUS and RPL13A loci showed that DRIPc-seq signals appeared downstream of the TSS sites and distributed mainly at the gene body and TES regions (Fig. 8B). Instead, R loop CUT&Tag used the in situ capture strategy and could capture the high signals at the promoter regions and some signals at the gene body and TES. The promoter-associated R loop signals most likely come from the paused RNA polymerases, which localize at the downstream of TSS sites. Genome-wide analysis of R loop signals by the GST-His6-2HBD and S9.6 in DRIPc-seq and CUT&Tag (Fig. 8, C to F) confirmed the global profiling differences between the ex vivo and in situ capture strategies.

(A) Workflow of DRIPc-seq with GST-His6-2HBD or S9.6 combined with random fragmentation of genomic DNA by NEB dsDNA fragmentase. IP, immunoprecipitation. (B) Genome browser tracks of DRIPc-seq and R loop CUT&Tag coverage at the FUS and RPL13A loci detected by GST-His6-2HBD and S9.6. Signals were normalized by reads per million. (C and D) Heatmap analysis of DRIPc-seq (ex vivo) and R loop CUT&Tag (native, in situ) at all the protein-coding genes by GST-His6-2HBD (C) or S9.6 (D). (E and F) Metagene plots of DRIPc-seq and R loop CUT&Tag by GST-His6-2HBD (E) or S9.6 (F).

Both GST-His6-2HBD and S9.6 showed CUT&Tag signals upstream of the TSS sites. Compared to the DRIPc-seq method, which detects the RNA moiety of DNA-RNA hybrid, the CUT&Tag used the proximal tagmentation strategy and the pA-Tn5 at the binding sites of sensor protein could access the nearby regions and add the adaptors to the nearby DNA and DNA-RNA hybrids. The library size distribution analysis (Fig. 3D) showed that the CUT&Tag libraries had an average size of 405 bp. After deduction of the sequencing adaptors, the insertion fragments are around 269 bp and could cover the regions upstream of TSS and even the downstream of Pol II pausing sites. Another possible explanation for these R loop signals upstream of TSS is the bidirectional transcription at the promoter regions, which has been reported in R-ChIP (23), RR-ChIP (25) and DRIPc-seq (15). We also noticed the difference between GST-His6-2HBD and S9.6 at the TES regions, suggesting that the R loops at TES may have unique characteristics that could be preferentially recognized by the S9.6 antibody in DRIPc-seq. Together, these data showed that the same R loop sensor proteins generated distinct R loop genomic profiling with the ex vivo and in situ capture strategies.

In this study, we constructed specific R loop sensor proteins using the HBD domain of RNase H1 and showed that these sensors bound specifically in vitro to DNA-RNA hybrids and R loops (Fig. 1 and fig. S1), indicating their potential usefulness as new R loop mapping sensors. With GST-His6-2HBD, we established a sensor proteinbased DRIPc-seq method that obtained similar R loop profiling to S9.6-based DRIPc-seq (Fig. 2 and fig. S2), showing that GST-His6-2HBD is superior to the catalytically inactive RNase H1 in affinity pulldown assays (8, 12). To eliminate concerns with the bias of fragmentation by restriction enzymes (21), we developed alternative strategies for native R loop mapping through establishing a genome-wide R loop CUT&Tag. We compared our system with other conventional R loop methods and investigated the effects of capture strategies on R loop profiling.

R loop CUT&Tag is a sensitive, reproducible, and convenient method to map genome-wide native R loops with high resolution. We tested R loop CUT&Tag with three different approaches and found that the approach combining anti-HisTag antibody and GST-His6-2HBD protein generated a superior resolution and the highest signals in R loop CUT&Tag analysis (Fig. 4). We also systematically compared the R loop signals detected by CUT&Tag methods using MapR, R-ChIP, and DRIPc-seq (Fig. 6 and fig. S4). Our results showed that CUT&Tag, MapR, and R-ChIP signals were concentrated at the TSS sites, while DRIPc-seq did not show this pattern of distribution (Fig. 6). We also found that the overall enrichment of R loop signals by CUT&Tag was much higher than other R loop mapping methods (Fig. 6, E and G). Furthermore, we optimized the DRIPc-seq method with random fragmentation of genomic DNA by dsDNA fragmentase and compared the ex vivo and in situ R loop detection strategies (Fig. 8). Ex vivo DRIPc-seq detected signals predominantly at the gene body and TES regions. This result may be explained by the relatively short and unstable R loops formed at the promoter due to the DNA sequence and topology (24, 38), while the R loops at the gene body and TES may be longer and relatively stable. Besides, RNase H1 was shown to be recruited to the promoter regions, which may degrade R loops and make the R loops at promoter regions highly dynamic (24). Moreover, the genomic DNA purification and fragmentation steps during ex vivo R loop capturing may damage the R loops at promoters. All of these factors could lead to the loss of R loop signals at the TSS and result in an enriched R loop profile at gene body and TES regions in DRIPc-seq (Fig. 8). Besides, since the RNA strands of R loops near the promoter are relatively shorter, it is also possible that the less efficiency of complementary DNA conversion and amplification of short RNA molecules caused the lack of signals at TSS in DRIPc-seq. In contrast, R loop CUT&Tag takes advantage of the in situ capture strategy and is able to capture the prominent signals at the promoter regions and some signals at the gene body and TES. In summary, we revealed that even the same R loop sensor proteins could generate distinct R loop profiles in the ex vivo DRIPc-seq and in situ CUT&Tag analysis, suggesting that the R loop capture strategies, instead of the specificity of S9.6 and RNase H1, are the major contributing factors to the discrepancies within different R loop mapping methodologies.

Although R loop CUT&Tag could detect a subset of genes with R loop signals at the gene body, neither R-ChIP nor MapR showed a similar bimodal distribution pattern, suggesting that R loop CUT&Tag is more sensitive than R-ChIP and MapR in R loop detection at the gene body regions (Fig. 7). The enriched key cellular processes (Fig. 7K) indicate that R loops at their gene body regions may participate in the regulation of various key biological processes. These genes were positively correlated with PRO-seq and H3K36me3 signals (Fig. 7, I and J), suggesting that these R loops may associate with transcription elongation. R loops have been shown to impair transcription elongation through functioning as roadblocks for RNA polymerases (27, 28). Besides, R loop induction is correlated with transcriptional pausing and elevated Pol II pausing at TSS, which allows for increased R loop formation (24). The misregulation of R loops and transcription elongation has been implicated in cancer and other human diseases. Mechanistic understanding of transcription elongation and R loop regulation is therapeutically relevant (29). Although the R loops at enhancers are transient due to the short-lived nature of enhancer RNAs (39) and the low transcriptional output of these cis-elements, the R loop CUT&Tag is capable of detecting the R loops at the enhancers (Fig. 7, L and M). R loops at enhancers were reported to promote antisense long noncoding RNA generation, modulate enhancer activities, and regulate cell differentiation and preprogramming (25, 3941). Our R loop mapping method could facilitate the mechanistic studies of enhancer R loops in gene transcription, DNA replication, DNA mutagenesis, enhanceropathies (42), as well as lineage specification and pluripotency.

R loop CUT&Tag is relatively easier and more straightforward than other enrichment-based R loop mapping methods such as DRIPc-seq and R-ChIP. It does not need fixation, sonication, restriction digestion, or generation of stable transgenic cell lines, and it only takes less than a day from cell collection to library preparation. The CUT&Tag analysis starts with half a million cells, which is far less than the minimal requirement of DRIPc-seq and R-ChIP methods, and it allows further optimization with even fewer cells. Thus, our method provides possibilities of genome-wide mapping of the native R loops with limited materials. Moreover, the unique characteristics of Tn5 transposase provide great specificity for R loop CUT&Tag analysis. Tn5 has been widely used in sequencing library preparation for rapid processing and low sample input requirement of dsDNA. In addition to its canonical function in dsDNA tagmentation, Tn5 transposase was recently shown to bind and effectively transpose both strands of DNA-RNA hybrids, which can be amplified for library preparation after strand displacement, avoiding many time-consuming steps (30, 31). Since Tn5 transposase does not react with ssRNA or ssDNA, there are no concerns with the possible RNA contamination or the off-target effect of HBD or S9.6 at loci with ssDNA. Tn5 has not been reported to transpose dsRNA, and even Tn5 could potentially react with dsRNA and ligate the adapters to dsRNA, the strands of the products are prevented from being displaced and amplified by Bst 2.0 and Q5 DNA polymerases. RNase A digestion of RNA and DNA-RNA hybrids markedly abolished the R loop CUT&Tag signals (Fig. 4), demonstrating that R loop CUT&Tag signals were not contamination from tagmentation of accessible DNA (35). Using RNase H to digest DNA-RNA hybrids during the antibody binding process substantially reduced R loop signals (Fig. 5), indicating the specificity of GST-His6-2HBD and S9.6 in R loop CUT&Tag analysis. Although the current form of R loop CUT&Tag does not provide strand information about R loops, modification of CUT&Tag library preparation to sequence both DNA and RNA strands of R loops is likely to provide useful strand information and better resolution.

HEK293T cells were obtained from American Type Culture Collection and maintained in Dulbeccos modified Eagles media (Life Technologies) supplemented with 10% fetal bovine serum (LONSERA) and 1 penicillin-streptomycin (Life Technologies) at 5% CO2 at 37C. Drosophila S2 cells were maintained in Schneiders medium at 25C. The cells were routinely tested for mycoplasma contamination with the MycoBlue mycoplasma detector (Vazyme). The HBD coding region RNase H1 was amplified by the Phanta Max Super-Fidelity DNA polymerase (Vazyme) using the ppyCAG-RNASEH1-D210N vector (Addgene #111904) and then cloned into the pET16b vector to produce the pET16b-His6-HBD plasmid by Gibson assembly. The His6-HBD coding region was further amplified and cloned into the pGEX-2 T vector (Sigma-Aldrich) to generate the pGEX-GST-His6-HBD plasmid. A 5Glycine linker and another copy of the HBD coding region were cloned into the pGEX-GST-His6-HBD vector to produce the pGEX-GST-His6-2HBD plasmid. The N-terminal 3Flag-tagged protein A and Tn5 transposase coding sequence was amplified from the 3Flag-pA-Tn5-Fl plasmid (Addgene #124601) and subsequently cloned into the pET16b vector to create the His6-pA-3Flag-Tn5 expression plasmid.

The pGEX-GST-His6-HBD and pGEX-GST-His6-2HBD plasmids were individually transformed into the T7 Express lysY/Iq competent E. coli cells (NEB, C3013). The transformed colonies were picked and cultured in the 2YT medium containing ampicillin (100 g/ml) at 200 rpm in a 37C shaker. Protein expression was induced by 0.5 mM isopropyl--d-thiogalactopyranoside (IPTG) when the optical density at 600 nm (OD600) reached 0.6, and the culture was grown for an additional 5 hours at 200 rpm. Bacterial cell pellets were collected and lysed in 40 ml of HEX buffer [20 mM Hepes-NaOH (pH 7.5), 0.8 M NaCl, 10% glycerol, and 0.2% Triton X-100] supplemented with 1 cOmplete, EDTA-free protease inhibitor cocktails (Roche, 04693132001). Homogenization of lysates was performed with a high-pressure homogenizer at 5.5 MPa for 5 min. The supernatant was collected by centrifuging at 12,000 rpm and 4C for 30 min. The GST-His6-HBD and GST-His6-2HBD proteins were purified with the Ni-NTA beads 6FF (Smart Life Sciences) and eluted with the HEX buffer containing 250 mM imidazole. The eluted proteins were dialyzed against the HEX buffer and were concentrated with an Amicon Ultra-15 centrifugal filter unit (Millipore, UFC901008; 10-kDa cutoff). The GST-His6-HBD and GST-His6-2HBD proteins were further analyzed by SDSpolyacrylamide gel electrophoresis (PAGE) and Coomassie blue staining.

Alexa Fluor 488labeled DNA oligonucleotides, Cy3-labeled RNA oligonucleotides, and their reverse complement DNA and RNA oligos were synthesized by Sangon Biotech (table S3). Fluorescent probes were generated by annealing the fluorescently labeled oligos with or without their reverse complement oligos. To perform the binding assays, 30 nM probes were incubated with the recombinant GST-His6-HBD or GST-His6-2HBD proteins at 25C for 30 min in the binding buffer [20 mM Hepes-NaCl (pH 7.0), 100 mM NaCl, 5% glycerol, 10 mM dithiothreitol (DTT), and 0.5 mM EDTA] supplemented with sheared salmon sperm DNA (5 g/ml; Thermo Fisher Scientific, AM9680). The probe and protein probe were resolved in a 6% native polyacrylamide gel in 0.5 tris-borate-EDTA buffer (pH 9.5). The polyacrylamide gels were scanned with a Typhoon FLA-9500 (GE Healthcare) to detect the probe signals. Densitometry of bands was performed using ImageJ.

Biolayer interferometry assays were performed using an Octet Red96 with streptavidin biosensors (ForteBio, 18-5019). The DNA oligonucleotides were synthesized and labeled with biotin at the 5 end (5-[biotin]AGC GTG CCG TGC AAC AAC ATT ACA C-3). Biotin-labeled DNA oligos were annealed with the reverse complement RNA oligonucleotides RNA-25 to generate a biotin-labeled DNA-RNA hybrid. Kinetic titration series were performed in the interaction buffer [20 mM Hepes-NaOH (pH 7.5) and 200 mM NaCl]. The streptavidin biosensors were hydrated in the interaction buffer for 10 min at 25C. Following the initial 120-s baseline, the streptavidin biosensors were loaded with the biotin-labeled DNA-RNA hybrid for 300 s. Redundant probes were removed by a 200-s baseline adjustment. To measure the interaction between recombinant proteins and DNA-RNA hybrid, the duration time of association and dissociation was set to 600 s. GST-His6-2HBD proteins were serially diluted from 200 to 6.25 nM and loaded in parallel to measure the binding kinetics with DNA-RNA hybrid. Sensorgrams and sensor signals were analyzed by the ForteBio data analysis software (version 7.1).

The His6-pA-3Flag-Tn5 plasmid was chemically transformed into BL21 (DE3) competent bacteria cells. A single colony was picked and inoculated with 5 ml of LB medium containing ampicillin (100 g/ml). After overnight culture at 37C and 200 rpm, 5 ml of culture was transferred to 1 liter of LB medium supplemented with ampicillin (100 g/ml) and cultured at 37C and 200 rpm. Once the OD600 of the culture reached 0.6, 0.2 mM IPTG was added, and the culture was further induced at 23C and 200 rpm for 5 hours to induce the pA-Tn5 expression. BL21 E. coli was collected and resuspended in 20 ml of HXG buffer [20 mM Hepes-KOH (pH 7.2), 0.8 M NaCl, 10% glycerol, and 0.2% Triton X-100] supplemented with 1 EDTA-free protease inhibitor cocktails and subjected to high-pressure homogenization at 4.1 MPa for 5 min. The supernatant was harvested by centrifuging at 12,000 rpm and 4C for 30 min, and 0.1 ml of 10% poly(ethyleneimine) solution (Sigma-Aldrich, P3143) was added to precipitate bacterial DNA, which was further removed by centrifugation at 12,000 rpm and 4C for 10 min. The His-tagged pA-Tn5 was purified with the Ni-NTA beads 6FF (Smart Life Sciences) and eluted with the HXG buffer containing 250 mM imidazole. The eluted pA-Tn5 was dialyzed against 2 dialysis buffer [100 mM Hepes-KOH (pH 7.2), 0.2 M NaCl, 0.2 mM EDTA, 2 mM DTT, 0.2% Triton X-100, and 20% glycerol]. The His-tagged pA-Tn5 was concentrated with an Amicon Ultra-15 centrifugal filter unit (Millipore, UFC903008; 30-kDa cutoff) and diluted 1:1 with 100% glycerol. The purified pA-Tn5 protein was analyzed by SDS-PAGE and Coomassie blue staining and quantified by bicinchoninic acid protein assays.

The pA-Tn5 transposome assembly was performed as described previously (33). Briefly, the Tn5MErev (5-[phos]CTG TCT CTT ATA CAC ATC T-3), Tn5ME-A (5-TCG TCG GCA GCG TCA GAT GTG TAT AAG AGA CAG-3), and Tn5ME-B (5-GTC TCG TGG GCT CGG AGA TGT GTA TAA GAG ACA G-3) oligonucleotides were diluted with TE buffer [10 mM tris-HCl (pH 8.0) and 1 mM EDTA] to 400 mM. The mosaic end double-stranded oligonucleotides (Tn5MEDS-A/Tn5MEDS-B) were prepared by mixing equal volume of Tn5MErev with Tn5ME-A or Tn5ME-B and were annealed with a Bio-Rad T100 thermal cycler. To generate pA-Tn5 transposome complex, Tn5MEDS-A, Tn5MEDS-B, and purified pA-Tn5 were mixed at 1:1:1 with the final concentration of 37.5 M, individually. The mixture was incubated on a three-dimensional rotator at room temperature for 1 hour. The activity of pA-Tn5 transposome was confirmed by tagmentation of plasmid DNA in N-[Tris(hydroxymethyl)methyl]-3-aminopropanesulfonic acid (TAPS)-DMF buffer [10 mM TAPS-KOH (pH 8.3), 5 mM MgCl2, and 10% DMF].

CUT&Tag assays were performed as described previously (32, 33) with some modifications. Briefly, 5 105 cells were washed twice in 1.0 ml of wash buffer [20 mM Hepes (pH 7.5), 150 mM NaCl, 0.5 mM spermidine, and 1 protease inhibitors] by gentle pipetting. Ten microliters of concanavalin Acoated magnetic beads (Smart Life Sciences) were activated and then added to 5 105 cells with incubation at room temperature for 10 min. The supernatant was removed, and bead-bound cells were resuspended in 100 l of antibody buffer [20 mM Hepes (pH 7.5), 150 mM NaCl, 0.5 mM spermidine, 1 protease inhibitors, 0.05% digitonin, 0.01% NP-40, and 2 mM EDTA]. Two micrograms of recombinant GST-His6-2HBD protein or S9.6 (antiDNA-RNA hybrid antibody, clone S9.6; Millipore, MABE1095) was added to incubate with the bead-bound cells by rotating overnight at 4C. As controls, 10 g of RNase A (Takara) or 20 U of RNase H (NEB, M0297S) was added during the antibody incubation stage. After brief wash with dig-wash buffer [20 mM Hepes (pH 7.5), 150 mM NaCl, 0.5 mM spermidine, 1 protease inhibitors, 0.05% digitonin, and 0.01% NP-40] twice, the GST-His6-2HBDtreated groups were incubated with anti-HisTag mAb (ABclonal, AE003; 1:100 dilution) or antiGST-Tag mAb (ABclonal, AE006; 1:100 dilution), individually. The S9.6-treated groups were incubated with rabbit anti-mouse immunoglobulin G (IgG) antibody (final concentration, 10 g/ml). The antibody incubation was performed in 100 l of antibody buffer and was incubated at room temperature for 1 hour. Bead-bound cells were briefly washed three times with 200-l dig-wash buffer to remove the unbound antibodies. The mouse anti-rabbit IgG antibody or rabbit anti-mouse IgG antibody was diluted 100 (final concentration, 10 g/ml) and incubated with the cells for another 1 hour, followed by washing with 200 l of dig-wash buffer three times.

A 1:250 dilution of pA-Tn5 adapter complex (~15 M) was prepared in dig-300 buffer [20 mM Hepes (pH 7.5), 300 mM NaCl, 0.5 mM spermidine, 1 protease inhibitors, and 0.05% digitonin]. One hundred microliters of diluted pA-Tn5 complex was mixed with the bead-bound cells and was rotated at room temperature for 1 hour. Bead-bound cells were washed three times in 200 l of dig-300 buffer to remove unbound pA-Tn5 protein. Next, cells were resuspended in 40 l of tagmentation buffer [10 mM TAPS-NaOH (pH 8.5), 10 mM MgCl2, 10% DMF, and 0.85 mM ATP] and incubated at 37C for 1 hour. To stop the tagmentation reaction, 2.25 l of 0.5 M EDTA, 2.75 l of 10% SDS, and 0.5 l of proteinase K (20 mg/ml; Roche) were added and were further incubated at 55C for 60 min. The tagmentation products were purified with 1 Sera-Mag carboxylatemodified magnetic beads (Sigma-Aldrich, GE24152105050350) and were eluted in 10 l of 0.1% Tween 20. The eluent was mixed with 10 U of Bst 2.0 WarmStart DNA polymerase (NEB, M0538) in 1 Q5 polymerase reaction buffer and was incubated at 65C for 30 min to perform the strand displacement reaction. The reaction was then stopped by incubation at 80C for 20 min. To generate the sequencing libraries, the mixture was mixed with a universal i5 primer and a uniquely barcoded i7 primer and then amplified with the Q5 high-fidelity master mix (NEB, M0492). The libraries were size-selected with 0.56 to 0.85 Sera-Mag carboxylatemodified magnetic beads and subjected to LabChip DNA analysis and Illumina sequencing.

CUT&Tag reads were aligned to the human genome (UCSC hg38) with Bowtie version 1.1.2, allowing only uniquely mapping reads with up to two mismatches (43). The aligned reads were normalized to total reads aligned (reads per million). The track files were made with the bamCoverage command from deepTools 3.3.0 (44). For spike-in normalization, the reads were also aligned to the E. coli genome by Bowtie2 with the options (--end-to-end --very-sensitive --no-overlap --no-dovetail --no-mixed --no-discordant --phred 33 -I 10 -X 700) (43). The RNase A and RNase Htreated groups were normalized to their nontreated counterparts by scale factors. CUT&Tag peaks were called using MACS (model-based analysis of ChIP-seq) version 2.1.2 using default parameters and q value cutoff of 1 104 (45). The distribution of CUT&Tag peaks was annotated with the R package ChIPseeker. Heatmaps, metaplots, and metagene plots were made for the indicated windows using the average coverage (reads per million) (46).

TT-seq was performed as described (47, 48) with modifications. A total of 1 107 cells were labeled with 400 M 4-thiouridine (4sU; Sigma-Aldrich, T4509) in a CO2 incubator at 37C for 10 min and were quickly lysed with 4 ml of TRIzol (Invitrogen, 15596018). Total RNA was purified with chloroform extraction and precipitated with isopropyl alcohol and 5 l of glycogen (20 mg/ml; Roche, 10901393001). The extracted RNA was spiked-in with 4sU-labeled S2 RNA and was further fragmented by base hydrolysis in 0.2 M NaOH (15 min, on ice), neutralized by adding 1 volume of 1 M tris-HCl (pH 6.8) and precipitated with isopropyl alcohol. Biotinylation reaction of 4sU-labeled RNA was carried out in a total volume of 250 l, containing 100 g of total RNA, 10 mM Hepes (pH 7.5), 1 mM EDTA, and 5 g of biotin-XX-MTSEA (Biotium, 90066) dissolved in DMF (final concentration of DMF, 20%) at room temperature for 30 min.

After biotinylation, excess biotin reagents were removed by extraction with chloroform and phase lock gel. RNA supernatant was precipitated with a 1:10 volume of 5 M NaCl and an equal volume of isopropyl alcohol. The RNA pellet was resuspended in 200 l of RNase-free water. After denaturation of RNA samples at 65C for 5 min followed by rapid cooling on ice for 5 min, biotinylated RNA was purified using 50 l of Dynabeads MyOne streptavidin C1 (Thermo Fisher Scientific, 65001). MyOne streptavidin beads were incubated with RNA samples for 15 min with rotation at room temperature. Beads were then washed three times with wash buffer [10 mM tris-HCl (pH 7.4), 1 mM EDTA, 1 M NaCl, and 0.1% Tween 20], followed by one step wash at 65C. 4sU-RNA was eluted with 100 l of freshly made 100 mM DTT, followed by a second elution with an additional 100 l of 100 mM DTT.

The eluted RNA was purified with the Sera-Mag carboxylatemodified magnetic beads and was subjected to strand-specific RNA-seq library preparation. Libraries were made with the NEBNext Ultra RNA Library Prep Kit for Illumina and subjected to next-generation sequencing. TT-seq reads were aligned to the human genome (UCSC hg38) with Bowtie 1.1.2 (43), allowing only uniquely mapping reads with up to three mismatches within the 50-bp read. The resulting reads were normalized to total reads aligned (reads per million) for each strand with deepTools 3.3.0 (44). The reads coverage at indicated regions were calculated by bedtools multicov (version 2.25.0) or HTSeq-count and were then normalized to total reads aligned.

Chromatin-associated RNA-seq was performed as described before (49). Briefly, 10 million HEK293T cells were harvested via trypsin digestion and were washed twice with 10 ml of ice-cold phosphate-buffered saline. Cells were resuspended in 5 ml of ice-cold NUN buffer [20 mM Hepes (pH 7.9), 7.5 mM MgCl2, 0.2 mM EDTA, 300 mM NaCl, 1 M urea, 1% NP-40, 1 mM DTT, RNase inhibitor (20 U/ml), and 1 cOmplete EDTA-free protease inhibitor cocktails (Roche, 04693132001)] with gentle pipetting. The suspension was placed on ice for 10 min and centrifuged at 3000g for 5 min at 4C. The chromatin pellet was further washed with 10 ml of NUN buffer four times and lysed with 1 ml of TRIzol reagent. The lysates were heated to 65C to dissolve the chromatin pellets, and RNA extraction was performed according to the manufacturers instruction. The RNA was polyadenylation depleted with Oligo(dT)25 magnetic beads (NEB, #S1419S) and treated with RNase-free deoxyribonuclease I (DNase I) to remove potential mRNA and genomic DNA contamination. The RNA was then purified with phenol/chloroform extraction and ethanol precipitation. Five hundred nanograms of RNA was further ribodepleted with the Ribo-off rRNA depletion kit (Vazyme, #N406), and library preparation was performed with the NEBNext ultra RNA library prep kit for Illumina. Chromatin-associated RNA reads were aligned to the human genome (UCSC hg38) using Bowtie 1.1.2. For track files, reads were normalized by reads per million. Reads at all of the protein-coding genes were counted by HTSeq-count with the union model.

PRO-seq was performed as described previously (47, 50). Briefly, all four biotinylated nucleotides (PerkinElmer) were used at 25 mM for the nuclear run-on reaction. RNA 5 pyrophosphohydrolase (NEB, M0356S) was used to remove the RNA cap to facilitate the downstream library preparation. PRO-seq reads were mapped to the human genome (UCSC hg38) using Bowtie version 1.1.2, allowing only uniquely mapping reads with up to three mismatches (43). Aligned reads were then converted to strand-specific bigwig files with the bamCoverage command from deepTools 3.3.0 (44). PRO-seq genome browser track examples show coverage of the entire length of the read for visualization. The read counts at indicated regions were calculated by bedtools multicov (version 2.25.0). The heatmaps were generated with the indicated regions with ngs.plot or the computeMatrix command from deepTools 3.3.0 (44).

DRIPc-seq experiments were performed according to a previously published protocol (18) with modifications. A total of 8 106 293 T cells were harvested and resuspended in 1.6 ml of TE buffer including 50 l of 20% SDS and 5 l of proteinase K (20 mg/ml). After digestion at 37C for 12 hours, phenol/chloroform extraction and ethanol precipitation were performed to purify the genomic DNA. The DNA was further digested with NEB restriction enzymes (EcoR I, Ssp I, BsrG I, Xba I, and Hind III) or NEBNext dsDNA fragmentase (NEB, M0348). Eight micrograms of digested genomic DNA was incubated with 100 ng of GST-His6-2HBD protein or 20 g of S9.6 mAb in DRIP-binding buffer [10 mM NaPO4 (pH 7.0), 140 mM NaCl, and 0.05% Triton X-100] at 4C overnight. The 2HBD:DNA-RNA hybrid complexes and S9.6:hybrid complexes were purified with 20 l of glutathione magnetic agarose beads (Thermo Fisher Scientific, 78601) or protein A/G agarose at 4C for 4 hours with rotation. After extensive washes four times, the nucleic acids were eluted and purified as previously described (18).

For DRIPc-seq library preparation, the DNA molecules were digested with NEB DNase I for 1 hour at 37C, and the RNA molecules were recovered with ethanol precipitation. The libraries were prepared with the NEBNext Ultra Directional RNA Library Prep Kit and subjected to LabChip analysis and next-generation sequencing. DRIPc-seq reads were aligned to the human genome (UCSC hg38) with Bowtie 1.1.2, allowing only uniquely mapping reads with up to two mismatches within the first 50 nucleotides (43). The resulting reads were normalized with total reads aligned for visualization. The heatmaps were generated with the indicated regions with the computeMatrix and plotHeatmap commands from deepTools 3.3.0 (44). The read numbers at indicated regions were counted by the multicov command from bedtools v2.25.0 or HTSeq-count.

Quantitative real-time polymerase chain reaction (PCR) was performed in triplicate using a Jena qTOWER G real-time PCR thermal cycler. Primer sequences for all quantitative PCR reactions are RPL13A forward (5-AGG TGC CTT GCT CAC AGA GT-3), RPL13A reverse (5-GGT TGC ATT GCC CTC ATT AC-3), TFPT forward (5-TCT GGG AGT CCA AGC AGA CT-3), TFPT reverse (5-AAG GAG CCA CTG AAG GGT TT-3), EGR1 forward (5-GAA CGT TCA GCC TCG TTC TC-3), and EGR1 reverse (5-GGA AGG TGG AAG GAA ACA CA-3).

All quantitative results were analyzed with the test indicated in the figure legends, after confirming that the data met appropriate assumptions (normality, homogeneous variance, and independent sampling). All the P values are two tailed, and the data are presented as means SD. The peak or gene size (n) in the heatmaps indicates the number of peaks or genes included. In the violin plots, the white dot indicates the median, and the solid box indicates the interquartile range. The statistical tests were performed with R (version 3.6.1).

Acknowledgments: We thank the staffs at the Research Center for Medicine and Structural Biology of Wuhan University for technical assistance. We are grateful to D. Gao at the core facility of Wuhan Institute of Virology for biolayer interferometry advice and E. Smith at the Northwestern University Feinberg School of Medicine for helpful discussion. We thank S. Henikoff at the Division of Basic Sciences of Fred Hutchinson Cancer Research Center for the 3Flag-pA-Tn5-Fl plasmid. Funding: This study was supported by the National Key Research and Development Program of China Stem Cell and Translational Research (no. 2019YFA0111100) and the Thousand Youth Talents Plan awarded to K.L. and the Youth Program of National Natural Science Foundation of China (nos. 32001049 and 82000114) awarded to P.F. and Y.X. Author contributions: K.L., K.W., and P.F. conceived and designed the experiments. K.L., K.W., H.W., C.L., Y.X., and Q.L. conducted the experiments. Z.Y., W.W., and K.L. performed the bioinformatics and statistical analysis of the genomic data. K.W., P.F., and K.L. drafted the manuscript with the input from all authors. All authors contributed to editing the manuscript. Competing interests: The authors declare that they have no competing interests. Data and materials availability: The MapR, R-ChIP, H3K36me ChIP-seq, and DRIPc-seq raw data were downloaded from NCBI GEO: GSE120637, GSE97072, GSE145160, and GSE102474, respectively. The datasets generated during this study are available at NCBI GEO: GSE156400. Further information and requests for reagents may be directed to and will be fulfilled by the corresponding author K.L. upon request. All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials.

View post:
Genomic profiling of native R loops with a DNA-RNA hybrid recognition sensor - Science Advances

WASHINGTON (NewsNation Now) The White House COVID-19 response team announced Wednesday that the Biden administration will invest $1.6 billion to support testing in schools, increase genomic sequencing and manufacture testing supplies.

We need to test broadly and rapidly to turn the tide of this pandemic, said Carole Johnson, White House COVID-19 testing coordinator. But we still dont have enough testing and we dont have enough testing in all the places it needs to be.

$815 million will be used to increase domestic manufacturing of testing supplies, particularly those that are facing a shortage including molded plastics and filter pipette tips, the Biden administration said.

Nearly $200 million will be invested by the Centers for Disease Control and Prevention to increase virus genome sequencing to identify and track emerging variant virus strains throughout the country. This comes as CDC Director Rochelle Walensky confirmed that the variant strain first found in Bristol, England was reported in the United States.

$650 million will be used to expand testing in schools and underserved populations. The Department of Health and Human Services in partnership with the Department of Defense will use the money to expand testing opportunities for K-8 schools and underserved congregate settings, such as homeless shelters, according to the Biden administration.

Even though we dont feel that every teacher needs to be vaccinated before you can open a school, that doesnt take away from the fact that we strongly support the vaccination of teachers, said Dr. Anthony Fauci.

The CDC Friday provided a long-awaited road map for reopening schools emphasizing mask-wearing and social distancing and saying vaccination of teachers is important but not a prerequisite for reopening.

Agency officials were careful to say they are not calling for a mandate that all U.S. schools be reopened. But they said there is strong evidence now that in-person schooling can be done safely, especially at lower grade levels, and the guidance is targeted at schools that teach kindergarten up to 12th grade.

The guidance was issued as President Biden faces increasing pressure to deliver on his promise to get the majority of schools back to in-person learning by the end of his first 100 days in office. The White House said last week that a national strategy would be guided by science. Biden reiterated his stance at a Wisconsin town hall Tuesday night.

Asked when the nation would see kindergarten through eighth grades back to in-person learning five days a week, Biden said, Well be close to that at the end of the first 100 days. He said he expected many schools would push to stay open through the summer, but suggested reopening would take longer for high schools due to a higher risk of contagion among older students.

Biden alsoannounced a vaccination goal of 100 million coronavirus shots in his first 100 days in office.

New figures from the White House show the steady increase in the pace of vaccinations over President Joe Bidens first month in office.

Much of the increase, according to data from the Centers for Disease Control and Prevention, comes from people receiving their second dose of the approved vaccines from Moderna and Pfizer.

Biden is on track to beat his goal of 100 million injections in his first 100 days in office though the pace must pick up even further to meet his plans to vaccinate nearly all adults by the end of the summer.

More than 71 million vaccine doses have been distributed across the United States, with more than 55.2 million doses administered, according to the CDC.

As the average daily new virus cases dipped below 100,000 for the first time in months as the United States seeks to picture a return to life as it was pre-pandemic. There have been more than 27.7 million confirmed cases in the United States and nearly 490,000 Americans have died from the virus, according to data complied by Johns Hopkins University.

See the article here:
Biden administration to invest $1.6 billion to expand testing in schools, genomic sequencing - WGN TV Chicago

Ancient DNA has revolutionized how we understand human evolution, revealing how populations moved and interacted and introducing us to relatives like the Denisovans, a "ghost lineage" that we wouldn't realize existed if it weren't for discovering their DNA. But humans aren't the only ones who have left DNA behind in their bones, and the same analyses that worked for humans can work for any other group of species.

Today, the mammoths take their turn in the spotlight, helped by what appears to be the oldest DNA ever sequenced. DNA from three ancient molars, one likely to be over a million years old, has revealed that there is a ghost lineage of mammoths that interbred with distant relatives to produce the North American mammoth population.

Mammoths share something with humans: Like us, they started as an African population but spread across much of the planet. Having spread out much earlier, mammoth populations spent enough time separated from each other to form different species. After branching off from elephants, the mammoths first split into what are called southern and steppe species. Later still, adaptations to ice age climates produced the woolly mammoth and its close relative, the North American mammoth, called the Columbian mammoth. All of those species, however, are extinct, and the only living relatives are the elephants.

We have obtained DNA from two of these species, the woolly and Columbian mammoths. These revealed both a number of adaptations to cold climates and a small degree of interbreeding, as woolly mammoths made their way into North America and contributed a small amount (about 10 percent) to the genome of the Columbia population.

The new work focused on mammoth teeth found in Siberia, where conditions have favored both the preservation of remains and the preservation of the DNA they contain. The teeth come from layers of material that appear to have been deposited at the start of the most recent glacial period, which is when the ancestors of the woolly mammoth population should have been present in the area.

We don't have precise dates for any of the teeth, as they appear to be too old for carbon dating. Instead, dates have been inferred using a combination of the species present in the deposits and the known timing of flips in the orientation of Earth's magnetic field. In addition, the shape of the teeth provides some hints about what species they group with and some further indication of when they were deposited. In all, one tooth is likely to be at least 500,000 years old, another about a million years old, and a third somewhat older still.

Previously, the oldest DNA obtained from animal remains is roughly the age of the youngest of these samples. But the researchers were able to recover some elephant-like DNA from each of the molars, although it was badly fragmented, and many individual bases were damaged. Researchers were able to isolate the full mitochondrial genome for each of the three teeth, as each cell contains many copies of this genome in each of its mitochondria. Only fragments of the nuclear genome could be obtained, howeverat most, about 10 percent of one genome, and at worst under 2 percent. (Less than 2 percent is still tens of millions of individual bases.)

Using the differences between the mammoth and elephant DNA and assuming a constant rate of mutation, the research team was able to derive independent dates for when each of the animals that left a tooth must have lived. Based on the mitochondria genome, the dates were 1.6 million, 1.3 million, and 900,000 years ago. For the two that had enough nuclear genome to analyze, the dates were 1.3 million and 600,000 years ago. The DNA-based dates for these two lined up nicely with each other and the date of the material they were found in. The oldest sample might be older than the deposit it's in, and thus it might have been moved after death.

While these dates are fairly uncertain, they pretty clearly place two of the samples as the oldest DNA ever obtained from animals. And it would mean that these mammoths were living in Siberia shortly after ice-age conditions prevailed, although before there was a clear woolly mammoth lineage. They'd also predate the known appearance of mammoths in North America.

Continued here:
Million-Year-Old DNA Rewrites Mammoths' Evolutionary Tree - WIRED